Please login to the form below

Not currently logged in

New US guidelines to boost statin use but Crestor may miss out

American Heart Association and American College of Cardiology put emphasis on patient characteristics
AstraZeneca Crestor rosuvastatin

Long-awaited new guidelines on the use of statins were published in the US yesterday, and promise to dramatically increase prescribing of the cholesterol-lowering drugs.

The highly-regarded guidance from the American Heart Association (AHA) and American College of Cardiology (ACC) places more emphasis on patient characteristics such as age, gender, race and concomitant diseases and less on lab values for cholesterol levels in the blood.

The document looks at various treatments designed to reduce atherosclerotic cardiovascular risk in adults and - for the first time - includes stroke and diabetes among the factors that should lead to prescribing decisions.

All told, it is estimated that around a third of the entire US population would be eligible for statin treatment if the recommendations were applied to the letter. At the moment statins are prescribed for around a quarter of Americans aged over 40, but this could increase to 44 per cent of men and 22 per cent of women.

Analysts suggest, however, that the reduced importance of total and LDL cholesterol levels mean that some statins marketed on the back of for high potency - notably AstraZeneca's Crestor (rosuvastatin) - could actually see a brake on sales.

"With target LDL levels no longer a metric to push towards, Crestor's main differentiation will be blunted in our view," commented Savvas Neophytou of Panmure Gordon in a research note published this morning.

Specifically, the AHA/ACC recommendations focus on four patient groups: people with established atherosclerotic cardiovascular disease; those with LDL cholesterol levels of 190mg/dL or higher because of genetic risk; older people (aged 40 to 75) with type 2 diabetes; and those with a 10-year risk of heart disease greater than 7.5 per cent.

It also gives advice on the intensity of statin therapy that should be employed, with high-potency drugs such as Crestor and generically-available atorvastatin reserved for patients with atherosclerosis and LDL cholesterol levels above 190mg/dL.

People with diabetes can be treated with a moderate-intensity statin, while those at high risk of heart disease could receive either a moderate- or high-intensity drug.

"Crestor's unique selling point had been its efficacy, so treating to specific targets was a key driver for switching to more efficacious statins if cheaper generics did not work," noted Neophytou.

"This will no longer be the case," he added, noting that Panmure now expects Crestor sales of $5.1bn next year, declining to $4.5bn in fiscal 2015.

The product is expected to achieve sales of around $5.6bn this year, down from $6.2bn in 2012 mainly as a result of competition from generic atorvastatin.

View the new guidelines on statin use from the American Heart Association and the American College of Cardiology

Article by
Phil Taylor

13th November 2013

From: Sales, Regulatory, Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

Biopharma's Future: Made in China
The world’s second biggest pharma market is entering a new growth phase – but meeting its needs takes investment and expertise...
Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....